Virginia Solitano, Paola Facheris, Magnus Petersen, Ferdinando D'Amico, Michela Ortoncelli, Daniel Aletaha, Pablo A Olivera, Thomas Bieber, Sofia Ramiro, Subrata Ghosh, Maria Antonietta D'Agostino, Britta Siegmund, Isabelle Chary-Valckenaere, Ailsa Hart, Lorenzo Dagna, Fernando Magro, Renaud Felten, Paulo Gustavo Kotze, Vipul Jairath, Antonio Costanzo, Lars Erik Kristensen, Laurent Peyrin Biroulet, Silvio Danese
BACKGROUND AND AIMS: The Pharmacovigilance Risk Assessment Committee (PRAC) proposed measures to address severe side effects linked to Janus kinase inhibitors (JAKi) in immune-mediated inflammatory diseases (IMID). Use of these medications in individuals aged 65 and older, those at high cardiovascular risk, active or former long-term smokers, and those with increased cancer risk should be considered only if no alternatives exist. Caution is advised when administering JAKi to patients at risk of venous thromboembolism...
December 19, 2023: Autoimmunity Reviews